Revvity, Inc. Hits 52-Week Low at USD 81.23 Amid Declining Sales

Revvity, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 81.23 as of April 29, 2026. This marks a significant decline, with the stock's performance over the past year showing a decrease of 24.74%. In contrast, the S&P 500 has experienced a robust gain of 28.33% during the same period. The company's market capitalization stands at approximately USD 9,668 million, with a price-to-earnings (P/E) ratio of 34.00. Revvity's dividend yield is currently at 0.34%, and it maintains a debt-to-equity ratio of 0.32. However, the company has faced challenges in profitability, reflected in a return on equity of just 3.89%. Over the last five years, Revvity has reported a decline in net sales at an annual rate of 1.23%, alongside a decrease in operating profit of 2.67%. The stock's performance has consistently lagged behind the S&P 500, highlighting ongoing difficulties in achieving growth and efficiency within the competitive landscape of the pharmaceuticals and biotechnology industry.